Global Reversible Airway Diseases Treatment Market – Industry Trends and Forecast to 2030

Reversible Airway Diseases Treatment Market Analysis and Size

The reversible airway diseases include many diseases that don’t have any cure but can be treatable. As per the CDC statistics, asthma incidence has increased over the years. Also, as per the same source, in 2014, COPD is 4th leading cause of death in the U.S. market. Cardiovascular and respiratory diseases have affected many individuals globally, and is the top cause of death among the global population. COVID-19 also had left a major impact on the population and the market growth.

Data Bridge Market Research analyses a growth rate in the global reversible airway diseases treatment market in the forecast period 2023-2030. The expected CAGR of global reversible airway diseases treatment market tend to be around 6.50% in the mentioned forecast period. The market was valued at USD 79.8 billion in 2022, and it would grow upto USD 132.07 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Reversible Airway Diseases Treatment Market Scope and Segmentation

Market Definition

Reversible airway disease is a kind of lung diseases that is characterized by airway obstruction. These type of diseases namely chronic obstructive pulmonary diseases, cystic fibrosis bronchiectsis, asthma, and bronchitis have reversible obstructive component. The extreme contraction in smooth muscles leads to obstruction of smaller bronchi and large bronchioles. The collapsed airways in lungs causes problems in exhaling. The major symptoms include cough, dyspnea, fever, episodic wheezing, purulent sputum, and difficulty in breathing.

Global Reversible Airway Diseases Treatment Market Dynamics

Drivers

• High Prevalence of COPD

According to the WHO, the major cause of COPD is exposure to tobacco smoke, either through active smoking or passive smoking. As per the WHO statistics, chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, resulting into 3.23 million deaths in 2019. Approximately 90% of COPD deaths in those under 70 years of age mostly occur in low- and middle-income countries (LMIC).This boosts the market growth.

• Rising Adoption of Combination Therapy

There are several combination therapies that include LAMA-ICS, LABA-ICS, triple therapy, and other combination drugs. Adoption of combination therapy is growing, as it is more effective than separate use of bronchodilators and corticosteroids. Rise in the number of patients successfully treated with combination therapy who were not showing signs of recovery with bronchodilators or corticosteroid treatments is projected to boost the global market.

 Opportunities

• Increase in Asthma Cases

As per the CDC statistics, the occurrence of asthma getting increased over the years. The occurrence of asthma increased from 7.3% in 2001 to 8.4% by 2010. In the U.S., around 20 Mn are asthma patients and 1 in every 12 people suffers from asthma. As per the NCD alliance, 235 Mn people suffer from asthma globally. This creates more opportunity for the market growth.

• Higher Focus on Inhalational Dosage Form

Many of companies are focusing on the inhalational dosage forms due to its faster action and quick relief than the conventional dosage forms. Numerous companies are developing dosage forms to decrease the dosage errors and ease to use. For instance, ProAir HFA (albuterol sulfate) inhalational aerosol developed by Teva Pharmaceuticals Ltd., where the aerosol turns red when the inhaler's dosage is nearly empty.

Restraints/Challenges

• Lack of skilled professionals

The lack of qualified healthcare professionals unable to perform the treatments could limit the growth of the global reversible airway diseases treatment market over a forecast period.

• Side-Effects of immune-mediated inflammatory disease drugs

The adverse side-effects associated with the treatment process hamper the market growth. Effects such as skin rash and some immunosuppressive drugs are commonly witnessed in the patients.

This global reversible airway diseases treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global reversible airway diseases treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Reversible Airway Diseases Treatment Market

With the onset of COVID-19, numerous countries abandoned all non-emergency surgical procedures so that healthcare professionals only focus on patients with COVID-19. Thus, the market faced a huge loss during the pandemic. It has been witnessed that people suffering from reversible airway disease treatment have a comparatively higher risk of COVID-19-related death, critical care admission or death, and hospital admissions than people without reversible airway diseases treatment. In addition to this, several adults with the inflammatory joint disease had a higher increase in risk of all outcomes than those with inflammatory skin or bowel disease. Thus, COVID-19 had a major impact on the market.

Recent Development

• In January 2022, the first patient was enrolled in a phase 4 study which is comparing Yupelri (revefenacin) to Spiriva (tiotropium) for the improvement of lung health in adults having severe chronic obstructive pulmonary disease (COPD). The safety of these two approved once-daily COPD maintenance treatments that would be assessed as well. Yupelri is a bronchodilator that relaxes and widens the lung airways, making breathing easier. It is available as an inhalable solution through a nebulizer.

Global Reversible Airway Diseases Treatment Market Scope

The global reversible airway diseases treatment market is segmented on the basis of treatment, type, diseases, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Bronchodilators
• Cytotoxic Drugs
• Antibiotics
• Others

Treatment

• Chest X Ray
• CT Scan
• Lung Therapies
• Surgery Transplant
• Medications

Diseases

• Asthma
• Chronic Bronchitis
• Emphysema
• Cystic Fibrosis
• Bronchiolitis
• Others

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Reversible Airway Diseases Treatment Market Regional Analysis/Insights

The global reversible airway diseases treatment market is analyzed and market size insights and trends are provided by treatment, type, diseases, end-user and distribution channel as referenced above.

The major countries covered in the global reversible airway diseases treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the presence of key manufacturers of the product, increasing research and development activities, healthcare expenditure, and skilled professionals in the region.

Asia-Pacific is expected to account for the largest market due to increased new research and developments on reversible airway diseases treatment market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Reversible Airway Diseases Treatment Market Share Analysis

The global reversible airway diseases treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global reversible airway diseases treatment market

Key players operating in the global reversible airway diseases treatment market include:

• Pfizer Inc. (U.S.)
• Abbvie Inc. (U.S.)
• Novartis AG (Switzerland)
• Amgen Inc. (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Merck & Co Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• AstraZeneca (U.K.)
• Ampio Pharmaceuticals Inc. (U.S.)
• Lilly (U.S)
• Zydus Group (India)
• Akorn, Incorporated (U.S.)
• Sumitomo Dainippon (Japan)
• VIDA Diagnostics Inc. (U.S.)
• Nuvaira Inc (U.S.)
• Genentech, Inc (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)

Research Methodology: Global Reversible Airway Diseases Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

SKU-55974